
Index

A

- Acute disseminated encephalomyelitis (ADEM), 87–88
- Acute gastroenteritis (AGE)
 - aichi virus, 173
 - bufavirus, 174
 - clinical treatment, 157
 - enteric adenovirus
 - (*see* Enteric adenovirus)
 - etiology, 156
 - HAsV (*see* Astrovirus (HAsV))
 - mortality, 156
 - NoV (*see* Norovirus (NoV))
 - pathogens, 156
 - picornavirus, 174
 - polyomavirus, 174
 - recovirus, 174
 - risk factors, 157
 - RV (*see* Rotavirus (RV))
 - sapovirus (*see* Sapoviruses)
 - torovirus, 173
 - tusavirus, 174
- Acute generalized exanthemous pustulosis (AGEP), 77–79
- Acute lower respiratory tract infection (ALTRI)
 - acute viral bronchiolitis (*see* Acute viral bronchiolitis)
 - asthma, 40
 - differential diagnosis, 40, 41
 - fatality rates, 28
 - parent and caregiver education, 48
 - pneumonia (*see* Acute pneumonia (AP))
 - prevention, 46–47
- Acute otitis media (AOM), 15–16
- Acute pneumonia (AP)
 - antimicrobial therapy, 42
 - bacterial–viral interactions, 32–33
 - CAP, 28–29
 - chest radiograph, 37
 - clinical investigations, 38–39
 - common causes, 29
 - danger signs, 35
 - definition, 28
 - diagnosis, 34
 - epidemiology, 30–33
 - Haemophilus influenzae*, 30
 - in HIV-infected children, 36
 - indications, 35
 - management of, 35, 40–43
 - mortality rate, 28
 - mycobacterium tuberculosis, 30
 - oxygenation assessment, 35
 - risk factors, 28
 - RSV, 30, 31
 - Staphylococcus aureus*, 30
 - Streptococcus pneumoniae*, 29
 - symptoms, 34
- Acute rhinosinusitis (ARS)
 - acute bacterial rhinosinusitis, 11
 - acute viral rhinosinusitis, 11
 - definition, 11, 12
 - diagnosis, 12–13
 - sequelae, 13–14
 - symptomatology, 12
 - treatment, 13
- Acute viral bronchiolitis
 - bacterial–viral interactions, 32–33
 - blood tests, 39
 - chest radiograph, 37–38
 - diagnosis, 34, 36
 - epidemiology, 30–33
 - hematological testing, 39
 - HMPV, 30

- Acute viral bronchiolitis (*cont.*)
 influenza and parainfluenza, 30
 management, 43–45
 NPAs, 39
 pathophysiology, 33–34
 risk factors, 39, 40
 RSV, 30, 31
 RV, 30, 31
- Acute viral laryngotracheitis, 18
- Acyclovir
 CMV, 113
 CNS, viral infections, 104, 107
 eczema herpeticum, 61
 HSV hepatitis, 201
- Adrenalin, 44
- Aichi virus, 173
- ALTRI. *See* Acute lower respiratory tract infection (ALTRI)
- Aminopenicillin, 65
- Amoxicillin
 acute viral rhinosinusitis, 13
 ALTRI, 41, 42
 EBV, 65
- Angiotensin converting enzyme inhibitor (ACE-I), 137
- Angiotensin II receptor blocker (ARB), 137
- AP. *See* Acute pneumonia (AP)
- Arbovirus (ARthropod-BORne), 86, 94, 105, 109, 114, 115
- ARS. *See* Acute rhinosinusitis (ARS)
- Asthma, 6, 40
- Astrovirus (HAstV)
 clinical features, 171
 diagnosis, 171
 prevention, 171
 virus description, 170–171
- Autoimmune encephalitis, 88–89, 97, 100, 108, 111
- Avian influenza, 49
- B**
- Babinski sign, 86, 87
- Ball-valve mechanism, 34
- Beta-blocker therapy, 137
- Bickerstaff's encephalitis, 88, 100
- BK virus, 85, 86
- Blood-brain barrier (BBB), 94, 95, 97, 102, 118
- Blood-cerebrospinal fluid barrier (BCSFB), 95, 117
- Bocavirus, 2, 3
- Brain stem encephalitis, 88
- Bronchiolitis. *See* Acute viral bronchiolitis
- Bufavirus, 174
- C**
- California Encephalitis Project, 88, 111, 112
- Canadian acute viral bronchiolitis management algorithm, 45
- Cardiac infections
 in HIV patients, 144–145
 myocarditis (*see* Myocarditis)
 pericarditis (*see* Pericarditis)
 viral endocarditis, 144
- Cardiac magnetic resonance imaging (CMR), 132–135
- Central nervous system (CNS), viral infections
 ADEM, 87–88
 autoimmune encephalitis, 88–89
 brain stem encephalitis, 88
 classification, of viruses, 94
 clinical manifestations, 91–93
 cardiac manifestations, 99
 encephalopathy, 97
 flaccid paralysis, 98
 focal neurological signs, 97
 gastrointestinal symptoms, 99
 meningeal irritation, 97
 myositis, 99
 raised intracranial pressure, 98
 respiratory symptoms, 99
 seizures, 98
 skin manifestations, 98–99
 complications, 108–109
- CT, 105
- diagnostic procedures
 biochemistry, 102–103
 cell types, 103
 chemokines, 104
 cytokines, 104
 LP, 100–101
 mediators role, 104
 microbiology, 103–104
 serology, 105
- differential diagnoses, 99–100
- EEG, 106
- encephalitis, 85–86
- epidemiology, 89–90
- flaviviridae, 114–115
- global distribution, of viruses, 91–93
- herpesviridae, 110
 CMV, 113
 cytomegalovirus, 113
 EBV, 114
 HHV-6, 113–114
 HSV, 110–112
 VZV, 112–113
- HIV, 106

- H1N1 flu virus, 119
 influenza viruses, 119
 meningitis, 86
 meningoencephalitis, 86
 MRI, 105
 myelitis, 86
 myelopathy, 86–87
 paramyxoviridae
 measles virus, 115–116
 mumps virus, 116
 pathogenesis, 90, 94–97
 picornaviridae
 enteroviruses, 116–117
 human parechovirus, 117
 polyomaviridae, 114
 prevention, 109–110
 prognosis, 108–109
 retroviridae, 117–118
 rhabdoviridae, 118
 rotavirus, 119
 togaviridae, 118
 treatment, 106
 antiviral treatment, 107–108
 autoimmune encephalitis, 108
 novel therapies, 108
 viral etiology, 90
 viral tropism, 96
 CMV. *See* Cytomegalovirus (CMV)
 Common cold, 10–12
 Community acquired pneumonia (CAP), 28–29
 Coxsackie viruses
 clinical presentation, 207
 diagnosis, 207
 eczema coxsackium, 74
 epidemiology, 206–207
 HFMD, 73
 prevention, 207
 transmission, 206–207
 treatment, 207
 virus structure, 206
 Cytomegalovirus (CMV), 36, 49
 clinical presentation, 202
 CNS, 113
 diagnosis, 202–203
 epidemiology, 201
 prevention, 203
 transmission, 201–202
 treatment, 203
 virus structure, 201
- D**
 Dexamethasone, 18
 Dilated cardiomyopathy (DCM), 134, 138
- Double stranded RNA (dsRNA), 157, 158
 Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, 67–69
- E**
 Eczema
 coxsackium, 74
 herpeticum, 60–61
 EFE. *See* Endocardial fibroelastosis (EFE)
 EMB. *See* Endomyocardial biopsy (EMB)
 Encephalomyelitis, 84, 86, 87, 114
 Endocardial fibroelastosis (EFE),
 127, 138
 Endomyocardial biopsy (EMB),
 134, 135, 137
 Enteric adenovirus
 clinical features, 172
 diagnosis, 172
 prevention, 172
 virus description, 172
 Enterovirus D68 (EV-D68) acute respiratory
 illness, 49
 Enteroviruses, 116–117
 Epiglottitis, 19–20
 Epstein–Barr virus (EBV)
 clinical presentation, 204
 CNS, 114
 diagnosis, 204–205
 epidemiology, 203–204
 PAC, 65
 prevention, 206
 reaction with aminopenicillins, 65
 transmission, 203
 treatment, 205–206
 Erythema infectiosum, 71–72
 Erythema multiforme (EM), 61–62
 Exanthems. *See* Viral exanthems
 Expanded programme on immunisation (EPI),
 161, 180, 189, 190
- F**
 Flaccid paralysis, 98
 Flaviviridae, 94, 114–115
 Frank-Starling curve, 136
- G**
 G3(RV3), 162
 Gastroenteritis. *See* Acute gastroenteritis (AGE)
 German measles. *See* Rubella
 Gianotti–Crosti syndrome, 65, 66

H

- Hand-foot-mouth disease (HFMD), 73
- Hantavirus pulmonary syndrome (HPS), 49
- HAV. *See* Hepatitis A virus (HAV)
- HBV. *See* Hepatitis B virus (HBV)
- HCV. *See* Hepatitis C virus (HCV)
- HDV. *See* Hepatitis D virus (HDV)
- Hendra virus, 93, 115
- Hepatitis
 - clinical symptoms, 178
 - CMV (*see* Cytomegalovirus (CMV))
 - coxsackie (*see* Coxsackie viruses)
 - EBV (*see* Epstein–Barr virus (EBV))
 - effective therapy, 178
 - HAV (*see* Hepatitis A virus (HAV))
 - HBV (*see* Hepatitis B virus (HBV))
 - HCV (*see* Hepatitis C virus (HCV))
 - HDV (*see* Hepatitis D virus (HDV))
 - HEV (*see* Hepatitis E virus (HEV))
 - HSV-1 and HSV-2 (*see* Herpes simplex virus (HSV))
- Hepatitis A virus (HAV)
 - clinical presentations, 179
 - complications
 - cholestatic hepatitis, 180
 - fulminant hepatitis, 179–180
 - relapsing hepatitis, 180
 - diagnosis, 180
 - epidemiology, 178
 - prevention, 180–181
 - transmission, 178
 - treatment, 181
 - virus structure, 178
- Hepatitis B virus (HBV)
 - acute
 - clinical manifestations, 183
 - convalescent phase, 184
 - diagnosis, 186
 - early prodromal phase, 183
 - icteric phase, 184
 - management, 187
 - preicteric phase, 183
 - chronic
 - diagnosis, 186
 - management, 187–188
 - physical examination, 184
 - clinical presentations, 183
 - extrahepatic manifestations, 186
 - fulminant, 184
 - HIV/HBV co-infection, 186
 - management, 187–188
 - prevalence, 181
 - prevention
 - EPI, 189–190
 - mother to child transmission, 190–191
 - PEP, 191
 - universal vaccination efficacy, 190
 - transmission
 - horizontal, 182
 - percutaneous, 183
 - perinatal, 182
 - sexual, 182
 - treatment
 - indications for, 188–189
 - options, 189
 - virus structure, 181–182
- Hepatitis C virus (HCV)
 - clinical presentations, 192–193
 - diagnosis, 194
 - extrahepatic manifestations, 193–194
 - HIV/HCV co-infection, 194
 - pre-treatment clinical evaluation, 194
 - prevention, 194
 - transmission
 - household, 192
 - non-parenteral, 192
 - parenteral, 192
 - treatment, 195
 - virus structure, 192
- Hepatitis D virus (HDV)
 - clinical presentations, 196
 - diagnosis, 196
 - epidemiology, 196
 - prevention, 197
 - transmission, 196
 - treatment, 197
- Hepatitis E virus (HEV)
 - clinical presentations, 197–198
 - diagnosis, 198
 - epidemiology, 197
 - prevention, 198
 - transmission, 197
 - treatment, 198
 - virus structure, 197
- Herpes genitalis, 59
- Herpes gladiatorum, 60
- Herpes labialis, 59
- Herpes simplex virus (HSV)
 - CNS, 110–112
 - eczema herpeticum, 60–61
 - erythema multiforme, 61–62
 - herpes genitalis, 59
 - herpes gladiatorum, 60
 - herpes labialis, 59
 - herpetic whitlow, 59, 60
 - HSV 1 and 2, 58
 - clinical presentations, 200
 - diagnosis, 200
 - epidemiology, 199
 - prevention, 201

transmission, 199
treatment, 201
oral HSV 1 infection, 58
primary infections, 58
Herpetic whitlow, 59, 60
HEV. *See* Hepatitis E virus (HEV)
HHV-6. *See* Human herpes virus-6 (HHV-6)
Hib vaccine, 19
H1N1 flu virus, 119
Hoovers sign, 36
HSV. *See* Herpes simplex virus (HSV)
Human herpes virus-6 (HHV-6), 113–114
Human immunodeficiency virus (HIV)
 cardiac infections, 144–145
 CNS infections, 106, 117–118
 HBV co-infection, 186, 193
 HCV co-infection, 194
Human metapneumovirus (HMPV), 30
Human parechovirus, 117
Human T-cell lymphotropic virus (HTLV),
 86, 91, 117
Hypertonic saline nebulization, 44
Hypoxemia, 42

I

Influenza vaccine, 46
Inotropic therapy, 136
Intravenous immunoglobulin (IVI_g), 70, 137, 144

J

Japanese encephalitis virus, 93, 94, 96, 109, 114
John Cunningham virus, 85, 86, 91, 94–96, 114
Jugular venous distention, 129, 141

K

Kussmaul's sign, 141

L

Lake Louise criteria, 133, 134
Lanzhou lamb rotavirus (LLR), 162
Late gadolinium enhancement (LGE), 133, 134
Lumbar puncture (LP), 86, 100–102, 104, 105,
 107, 111

M

Major Histocompatibility Complex (MHC), 135
Measles
 CNS, 115–116
 complications, 70
 modified measles, 70

 symptoms, 69–70
 vaccination, 70
Meningitis, 4, 86, 98, 100, 103, 116
Meningoencephalitis, 86
MHC. *See* Major Histocompatibility
 Complex (MHC)
Middle East respiratory syndrome (MERS), 49
Miller–Fisher syndrome, 88
Molluscum contagiosum, 75–76
Montelukast, 44
Motavizumab, 10
Mumps virus, 90, 92, 94–96, 99, 109, 116, 139
Mycobacterium tuberculosis, 30
Myelitis, 86
Myelopathy, 86–87
Myocarditis
 acute, 128
 chronic, 128–129
 definition, 125
 differential diagnosis, 135, 136
 echocardiography, 132
 EKG, 131
 EMB, 134–135
 epidemiology, 126
 etiology, 126
 laboratory evaluation, 130–131
 pathology, 127
 pathophysiology, 127–128
 physical examination
 abdomen, 129, 130
 cardiac, 129, 130
 extremities, 129, 130
 pulmonary, 129, 130
 skin, 129, 130
 vital signs, 129
 radiologic studies
 CMR, 132–135
 CXR, 132, 133
 treatment
 ACE-I, 137
 activity restriction, 138
 beta-blocker therapy, 137
 cardiac transplantation, 137–138
 directed therapy, 136
 diuresis, 135–137
 Frank–Starling curve, 136
 immunomodulation, 137
 immunosuppressive therapy, 137
 inotropic therapy, 136
 IVI_g, 137
 trials, 137
 vaccination, 138
 VAD, 136
 viruses, 126
Myositis, 99

N

- Nasopharyngeal aspirates (NPAs), 39
- National Collegiate Athletic Association (NCAA) guidelines, 60
- Nebulized bronchodilator therapy, 40
- Nipah virus, 93, 94, 96, 115
- Nonsteroidal anti-inflammatory drugs (NSAIDs), 137, 143, 144
- Norovirus (NoV)
 - African countries, 164, 165
 - clinical study, 165–166
 - diagnosis, 166–167
 - epidemiology, 164
 - immunity to, 167–168
 - incidence, 164
 - prevalence, 163–165
 - prevention, 168
 - structure, 164
 - treatment, 168
 - vaccination
 - development, challenges in, 168, 169
 - P particle vaccines, 170
 - VLPs, 169–170
- Norwalk virus. *See* Norovirus (NoV)

O

- Oseltamivir, 9
- Oxygen therapy, 42

P

- Palivizumab, 10, 46–47
- Papular acrodermatitis of childhood (PAC), 65, 66
- Papular pruritic glove and socks syndrome (PPGSS), 72
- Paramyxoviridae
 - measles virus, 115–116
 - mumps virus, 116
- Para-neoplastic syndromes, 88
- Parvovirus B19, 71–72
- PEP. *See* Post-exposure prophylaxis (PEP)
- Pericarditis
 - definition, 125
 - differential diagnosis, 143
 - echocardiography, 142–143
 - electrocardiography, 141–142
 - epidemiology, 138
 - etiology, 139
 - laboratory evaluation, 141
 - pathology, 139
 - pathophysiology, 139–140
 - physical examination
 - extremities, 141

- general appearance, 141
 - skin, 141
 - vital signs, 140–141
- presentation, 140
- radiologic studies, 143
- treatment, 143–144

Pharyngitis

- definition, 14
- diagnosis, 15
- sequelae, 15
- symptoms, 14
- treatment, 15
- viruses and bacteria, 14

Picornaviruses, 174**Pneumococcal conjugate vaccine (PCV), 32****Pneumocystis jiroveci, 36****Pneumonia. *See also* Acute pneumonia**

- alveolar, 32
- bacterial, 11, 29, 32
- pneumococcal, 32
- viral, 11

Polyomavirus, 174**Post-exposure prophylaxis (PEP), 191****R****Racemic epinephrine nebulizations, 18****Recovirus, 174****Respiratory syncytial virus (RSV)**

- ALTRI, 31, 33
- bronchiolitis, 31, 34
- disease prevention, 46–47
- mortality and morbidity, 30
- otitis media, 15–16
- pneumococcal infection, 32
- RSV-A, 30
- RSV-B, 30
- vaccines, 47–48
- viral AP, 30

Rhinosinusitis. *See* Acute rhinosinusitis (ARS)**Rhinovirus (RV)**

- acute viral bronchiolitis, 30, 31
- antibody response, 4
- asthma, 6
- average incubation period, 5
- chemokines, 7
- extracellular matrix collagen deposition, 7
- interferon release, 6–7
- in lower airways, 5
- phenotypic characteristics, 4
- prevention and treatment, 7–8
- proinflammatory mediators, 7
- RV-C, 8
- transmission, 5

Rhombencephalitis. *See* Brain stem encephalitis

Ribavirin, 9, 168, 195, 198

Roseola infantum (RI), 66, 67

Rotarix, 161, 163

Rotashield, 160, 162, 163

RotaTeq, 161, 163

ROTAVAC, 162

Rotavirus (RV)

- deaths, 157
- immune response, 159–160
- laboratory diagnosis, 160
- pathogenesis, 158–159
- prognosis, 159
- symptoms, 159
- transmission mode, 158
- vaccination
 - efficacy, 162–163
 - G3(RV3), 162
 - licensed, 161
 - LLR, 162
 - oral, 161
 - ROTAVAC, 162
 - safety, 163
 - virus structure, 157–158

RSV. *See* Respiratory syncytial virus (RSV)

Rubella, 70–71

RV. *See* Rhinovirus (RV)

S

Sapoviruses

- diagnosis, 173
- incubation period, 173
- mortality, 173

Seizures, 87–89, 98, 99, 101, 106, 109, 111, 113, 159

Severe acute respiratory syndrome (SARS), 48

Slow viruses. *See* Subacute sclerosing panencephalitis (SSPE)

Spasmodic croup, 18–19

SSPE. *See* Subacute sclerosing panencephalitis (SSPE)

Steeple sign, 18, 19

Strategic Advisory Group of Experts (SAGE), 161

Subacute sclerosing panencephalitis (SSPE), 84, 86, 106, 115, 116

Supraglottitis. *See* Epiglottitis

T

Tick-borne encephalitis virus, 93, 94, 96, 114, 115

Toroviruses, 173

Tusavirus, 174

U

Unilateral laterothoracic exanthem (ULTE), 76–77

Upper respiratory tract infections (URTI)

- acute infections, 2
- AOM, 15–16
- ARS, 11–14
- bacterial tracheitis, 20
- bocavirus, 2, 3
- common cold, 10–11
- diagnosis, 8–9, 18–19
- epiglottitis, 19–20
- human metapneumovirus, 2, 3
- obstructive conditions
 - laryngeal site, 17
 - symptomatology, 18
 - viral croup, 18
- pharyngitis, 14–16
- RV (*see* Rhinovirus (RV))
- transmission, 3
- treatment, 9–10

V

Vaccination

- for ALTRI, 46
- Asia, 162
- CNS, 109
- HAV, 180
- HBV, 189–191
- Hib vaccine, 19
- influenza vaccine, 46
- MMR vaccine, 70
- myocarditis, 138
- NoV
 - challenges, 169
 - P particles, 170
 - VLPs, 169–170
- PCV, 32
- RSV vaccines and maternal vaccination, 47–48
- RV
 - efficacy, 162–163
 - oral vaccine, 160
 - restricted license/in development, 162
 - RotaRix, 161, 163
 - RotaTeq, 161, 163
 - safety, 163
 - for VZV, 63–64
- Varicella Zoster virus (VZV)
 - CNS, 112–113
 - herpes Zoster, 64
 - vaccination, 63–64
 - varicella, 62–64

Ventricular assist devices (VAD), 136

Viral croup, 18

Viral exanthems

 AGEP, 77–79

 Coxsackie viruses, 72–74

 DRESS syndrome, 67–69

 EBV, 65

 herpes viruses, 58–62

 measles virus, 69–70

 molluscum contagiosum virus, 75–76

 nonspecific viral exanthems, 79

 parvovirus B19, 71–72

 pityriasis rosea, 67, 68

 roseola infantum, 66, 67

 rubella virus, 70–71

 ULTE, 76–77

 VZV, 62–64

Viral tropism, in CNS, 96

Virus-like particles (VLPs), 168–170

W

West Nile virus (WNV), 114, 115

Winter vomiting disease. *See* Norovirus (NoV)

Z

Zanamivir, 9